TOE-1: A Promising Drug Target and Biomarker for the Treatment of Neoplasia

Target Name: TOE1

NCBI ID: G114034

TOE1

TOE-1: A Promising Drug Target and Biomarker for the Treatment of Neoplasia

Introduction

Neoplasia, the formation of cancerous tissue in the body, is a leading cause of morbidity and mortality worldwide. The development of new treatments for cancer is crucial for improving survival rates and quality of life. One promising drug target for cancer treatment is the oncogene- specific gene expression (TOE) gene family, which encodes for proteins involved in various cellular processes that are essential for cancer growth and progression. TOE1, a member of the TOE gene family, has emerged as a promising drug target due to its unique structure, expression patterns, and functions.

Structure and Expression

The TOE gene family consists of four closely related genes: TOE1, TOE2, TOE3, and TOE4. These genes encode for proteins that share a conserved catalytic core and a unique N-terminus. The conserved catalytic core consists of a nucleotide-binding oligomerization domain (NBO), a helix-turn-helix (HTH) domain, and a C-terminal hypervariable region (HVR). The NBO domain is responsible for the protein's catalytic activity, while the HTH domain plays a structural role. The HVR is unique to each gene and is involved in protein-protein interactions and modulation of cellular processes.

TOE1, the first gene in the TOE gene family, was identified as a potential drug target due to its unique expression patterns. TOE1 is predominantly expressed in various tissues of the body, including skeletal muscles, heart, brain, andtestes. It is also expressed in various types of cancer, including breast, lung, and colorectal cancer. TOE1 has been shown to play a role in various cellular processes, including cell growth, differentiation, angiogenesis, and response to stimuli.

Expression and regulation

TOE1 is involved in various cellular processes that are critical for cancer growth and progression. It is a transcription factor that regulates gene expression by binding to specific DNA sequences. TOE1 has been shown to play a role in the regulation of cell cycle progression, cell growth , and apoptosis. It is also involved in the regulation of angiogenesis, where it promotes blood vessel formation and maintenance.

In addition to its role in cellular processes, TOE1 is also a potent drug target due to its unique expression patterns. TOE1 has been shown to be highly expressed in various types of cancer, including breast, lung, and colorectal cancer. It is also expressed in various tissues of the body, including skeletal muscles, heart, brain, and tests. This makes it an attractive target for cancer treatment.

Drugs that target TOE1 have the potential to inhibit its catalytic activity and disrupt its role in various cellular processes. This could lead to a reduction in cancer cell growth and a decrease in the spread of cancer to other tissues.

Conclusion

In conclusion, TOE1 is a promising drug target for cancer treatment due to its unique structure, expression patterns, and functions. The identification of TOE1 as a potential drug target has the potential to improve survival rates and quality of life for cancer patients. Further research is needed to fully understand the role of TOE1 in cancer treatment and to develop effective drugs that target this protein.

Protein Name: Target Of EGR1, Exonuclease

Functions: Inhibits cell growth rate and cell cycle. Induces CDKN1A expression as well as TGF-beta expression. Mediates the inhibitory growth effect of EGR1. Involved in the maturation of snRNAs and snRNA 3'-tail processing (PubMed:28092684)

The "TOE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TOE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets